系统性红斑狼疮靶向治疗研究进展

doi:10.35541/cjd.20240530

Abstract

Abstract: 【Abstract】 The exploration of novel targeted therapies for systemic lupus erythematosus （SLE） has always been a research hot topic in China and other countries. In recent years, there has been an increasingly in?depth understanding of the pathogenesis of SLE. The approval of belimumab, telitacicept, and anifrolumab for clinical applications marked a breakthrough in the treatment of SLE. In addition, novel agents targeting other B?cell/plasma cell antigens, T cells, neutrophils, and multiple inflammatory signaling pathways are emerging, which may provide more treatment options for SLE. This review summarizes research progress in targeted therapies for SLE based on the latest clinical trials, providing a basis for individualized treatment of SLE.

Key words: Lupus erythematosus, systemic, Targeted treatment, Biologic agent, Clinical trial

Xue Ke, Chen Jia, Li Bin. Targeted therapy for systemic lupus erythematosus[J]. Chinese Journal of Dermatology, 2025, 58(8): 781-784.doi:10.35541/cjd.20240530

References ［36］

［1］	Accapezzato D, Caccavale R, Paroli MP, et al. Advances in the pathogenesis and treatment of systemic lupus erythematosus［J］. Int J Mol Sci, 2023,24（7）:6578. doi: 10.3390/ijms24076578.
［2］	Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo⁃controlled, phase 3 trial［J］. Lancet, 2011,377（9767）:721⁃731. doi: 10.1016/S0140⁃6736（10）61354⁃2.
［3］	Furie R, Petri M, Zamani O, et al. A phaseⅢ, randomized, placebo⁃controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus［J］. Arthritis Rheum, 2011,63（12）:3918⁃3930. doi: 10.1002/art.30613.
［4］	Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately⁃to⁃severely active systemic lupus erythematosus: the randomized, double⁃blind, phaseⅡ/Ⅲ systemic lupus erythematosus evaluation of rituximab trial［J］. Arthritis Rheum, 2010,62（1）:222⁃233. doi: 10.1002/art.27233.
［5］	Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study［J］. Arthritis Rheum, 2012,64（4）:1215⁃1226. doi: 10.1002/art.34359.
［6］	中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南［J］. 中华内科杂志, 2020,59（3）:172⁃185. doi: 10.3760/cma.j.issn.0578⁃1426.2020.03.002.
［7］	Kraaij T, Arends EJ, van Dam LS, et al. Long⁃term effects of combined B⁃cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2⁃year results［J］. Nephrol Dial Transplant, 2021,36（8）:1474⁃1483. doi: 10.1093/ndt/gfaa117.
［8］	Atisha⁃Fregoso Y, Malkiel S, Harris KM, et al. PhaseⅡ randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis［J］. Arthritis Rheumatol, 2021,73（1）:121⁃131. doi: 10.1002/art.41466.
［9］	Merrill JT, Guthridge J, Smith M, et al. Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co⁃expression patterns: a double⁃blind, randomized, placebo⁃controlled, phase 2 trial［J］. Arthritis Rheumatol, 2023,75（12）:2185⁃2194. doi: 10.1002/art.42652.
［10］	Mougiakakos D, Krönke G, Völkl S, et al. CD19⁃targeted CAR T cells in refractory systemic lupus erythematosus［J］. N Engl J Med, 2021,385（6）:567⁃569. doi: 10.1056/NEJMc2107725.
［11］	Mackensen A, Müller F, Mougiakakos D, et al. Anti⁃CD19 CAR T cell therapy for refractory systemic lupus erythematosus［J］. Nat Med, 2022,28（10）:2124⁃2132. doi: 10.1038/s41591⁃022⁃02017⁃5.
［12］	Mougiakakos D. Allogeneic CAR T cells for autoimmune diseases: a glimpse into the future［J］. Signal Transduct Target Ther, 2024,9（1）:276. doi: 10.1038/s41392⁃024⁃01998⁃8.
［13］	Wang L, Yin H, Jiang J, et al. A rationally designed CD19 monoclonal antibody⁃triptolide conjugate for the treatment of systemic lupus erythematosus［J］. Acta Pharm Sin B, 2024,14（10）:4560⁃4576. doi: 10.1016/j.apsb.2024.06.024.
［14］	Alexander T, Krönke J, Cheng Q, et al. Teclistamab⁃induced remission in refractory systemic lupus erythematosus［J］. N Engl J Med, 2024,391（9）:864⁃866. doi: 10.1056/NEJMc2407150.
［15］	Isenberg D, Furie R, Jones NS, et al. Efficacy, safety, and pharmacodynamic effects of the Bruton's tyrosine kinase inhibitor fenebrutinib （GDC⁃0853） in systemic lupus erythematosus: results of a phaseⅡ, randomized, double⁃blind, placebo⁃controlled trial［J］. Arthritis Rheumatol, 2021,73（10）:1835⁃1846. doi: 10.1002/art.41811.
［16］	Wallace DJ, Dörner T, Pisetsky DS, et al. Efficacy and safety of the Bruton's tyrosine kinase inhibitor evobrutinib in systemic lupus erythematosus: results of a phaseⅡ, randomized, double⁃blind, placebo⁃controlled dose⁃ranging trial［J］. ACR Open Rheumatol, 2023,5（1）:38⁃48. doi: 10.1002/acr2.11511.
［17］	Merrill JT, Burgos⁃Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non⁃life⁃threatening manifestations of systemic lupus erythematosus: results of a twelve⁃month, multicenter, exploratory, phase Ⅱb, randomized, double⁃blind, placebo⁃controlled trial［J］. Arthritis Rheum, 2010,62（10）:3077⁃3087. doi: 10.1002/art.27601.
［18］	Furie RA, Leon G, Thomas M, et al. A phase 2, randomised, placebo⁃controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate⁃to⁃severe systemic lupus erythematosus, the PEARL⁃SC study［J］. Ann Rheum Dis, 2015,74（9）:1667⁃1675. doi: 10.1136/annrheumdis⁃2013⁃205144.
［19］	低剂量白细胞介素⁃2治疗系统性红斑狼疮专家组. 低剂量白细胞介素⁃2治疗系统性红斑狼疮的推荐意见［J］. 中华风湿病学杂志, 2019,23（1）:5⁃9. doi: 10.3760/cma.j.issn.1007⁃7480. 2019.01.002.
［20］	Miao N, Wang Z, Wang Q, et al. Oxidized mitochondrial DNA induces gasdermin D oligomerization in systemic lupus erythematosus［J］. Nat Commun, 2023,14（1）:872. doi: 10.1038/s41467⁃023⁃36522⁃z.
［21］	Li P, Jiang M, Li K, et al. Glutathione peroxidase 4⁃regulated neutrophil ferroptosis induces systemic autoimmunity［J］. Nat Immunol, 2021,22（9）:1107⁃1117. doi: 10.1038/s41590⁃021⁃00993⁃3.
［22］	Crow MK. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets［J］. Ann Rheum Dis, 2023,82（8）:999⁃1014. doi: 10.1136/ard⁃2022⁃223741.
［23］	Vital EM, Merrill JT, Morand EF, et al. Anifrolumab efficacy and safety by typeⅠ interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phaseⅢ trials［J］. Ann Rheum Dis, 2022,81（7）:951⁃961. doi: 10.1136/annrheumdis⁃2021⁃221425.
［24］	Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open⁃label phaseⅠdosage⁃escalation study［J］. Arthritis Rheum, 2010,62（2）:542⁃552. doi: 10.1002/art.27221.
［25］	Lorenzo⁃Vizcaya A, Isenberg DA. Clinical trials in systemic lupus erythematosus: the dilemma⁃why have phaseⅢ trials failed to confirm the promising results of phaseⅡ trials?［J］. Ann Rheum Dis, 2023,82（2）:169⁃174. doi: 10.1136/ard⁃2022⁃222839.
［26］	Yin H, Li L, Feng X, et al. 2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus［J］. Signal Transduct Target Ther, 2024,9（1）:323. doi: 10.1038/s41392⁃024⁃02017⁃6.
［27］	Rovin BH, Teng Y, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis （AURORA 1）: a double⁃blind, randomised, multicentre, placebo⁃controlled, phase 3 trial［J］. Lancet, 2021,397（10289）:2070⁃2080. doi: 10.1016/S0140⁃6736（21）00578⁃X.
［28］	Furie RA, van Vollenhoven RF, Kalunian K, et al. Trial of anti⁃BDCA2 antibody litifilimab for systemic lupus erythematosus［J］. N Engl J Med, 2022,387（10）:894⁃904. doi: 10.1056/NEJMoa2118025.
［29］	Piranavan P, Perl A. Improvement of renal and non⁃renal SLE outcome measures on sirolimus therapy ⁃ a 21⁃year follow⁃up study of 73 patients［J］. Clin Immunol, 2021,229:108781. doi: 10.1016/j.clim.2021.108781.
［30］	Zhang J, Guo Q, Dai D, et al. Rapamycin⁃encapsulated costimulatory ICOS/CD40L⁃bispecific nanoparticles restrict pathogenic helper T⁃B⁃cell interactions while in situ suppressing mTOR for lupus treatment［J］. Biomaterials, 2022,289:121766. doi: 10.1016/j.biomaterials.2022.121766.
［31］	Wang H, Li T, Sun F, et al. Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phaseⅠ/Ⅱ trial［J］. RMD Open, 2022,8（2）:e002686. doi: 10.1136/rmdopen⁃2022⁃002686.
［32］	Klopp⁃Schulze L, Shaw JV, Dong JQ, et al. Applying modeling and simulations for rational dose selection of novel Toll⁃like receptor 7/8 inhibitor enpatoran for indications of high medical need［J］. Clin Pharmacol Ther, 2022,112（2）:297⁃306. doi: 10. 1002/cpt.2606.
［33］	Gao X, Song Y, Du P, et al. Administration of a microRNA⁃21 inhibitor improves the lupus⁃like phenotype in MRL/lpr mice by repressing Tfh cell⁃mediated autoimmune responses［J］. Int Immunopharmacol, 2022,106:108578. doi: 10.1016/j.intimp.2022. 108578.
［34］	Kawato Y, Fukahori H, Nakamura K, et al. Potential benefit of the cathepsin S inhibitor, ASP1617, as a treatment for systemic lupus erythematosus［J］. Eur J Pharmacol, 2022,919:174826. doi: 10.1016/j.ejphar.2022.174826.
［35］	Xia Y, Jiang C, Yang M, et al. SB431542 alleviates lupus nephritis by regulating B cells and inhibiting the TLR9/TGFβ1/PDGFB signaling［J］. J Autoimmun, 2022,132:102894. doi: 10. 1016/j.jaut.2022.102894.
［36］	Knapp J, Braunstein M, Berg S, et al. HSPB5 suppresses renal inflammation and protects lupus⁃prone NZB/W F1 mice from severe renal damage［J］. Arthritis Res Ther, 2022,24（1）:267. doi: 10.1186/s13075⁃022⁃02958⁃9.

[1]	Xu Qiuyun, Ji Chao. Pyoderma gangrenosum-related systemic complications [J]. Chinese Journal of Dermatology, 2025, 58(4): 369-373.
[2]	Huang Xiaoyan, Su Juan, Chen Mingliang, Chen Xiang, Xiao Yi, Shen Minxue, . Efficacy of naloxone in improving health-related quality of life in patients with chronic arsenic exposure-related pruritus: a randomized, double-blind, placebo-controlled trial [J]. Chinese Journal of Dermatology, 2025, 58(2): 161-166.
[3]	Yao Wo, Wang Huiying. Lanadelumab in the treatment of hereditary angioedema: a systematic review of clinical trials [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230378-e20230378.
[4]	Chinese Society of Dermatology, China Dermatologist Association, Dermatology & Venereology Specialized Committee of Chinese Association of Integrative Medicine. Guidelines for the treatment of psoriasis with biologics and small-molecule drugs in China （2024） [J]. Chinese Journal of Dermatology, 2024, 57(11): 976-997.
[5]	Zhou Tong, Geng Songmei. Application of biologic agents in the treatment of bullous pemphigoid [J]. Chinese Journal of Dermatology, 2023, 56(8): 789-793.
[6]	Zhou Chu, Wen Long, Wang Peiru, Wang Xiuli, . Application of photoacoustic imaging in the diagnosis and treatment of skin tumors [J]. Chinese Journal of Dermatology, 2021, 54(3): 256-259.
[7]	Chinese Society of Dermatology, China Dermatologist Association, Dermatology & Venereology Specialized Committee of Chinese Association of Integrative Medicine. Guidelines for the treatment of psoriasis with biologic agents in China （2021） [J]. Chinese Journal of Dermatology, 2021, 54(12): 1033-1047.
[8]	Zhu Beibei, Li Jing, Huang Huiyao, Li Ning, Liu Lijun, Zhang Lihua, Huan Jing, Ni Qi, Hou Wei, Liu Yi, Yang Xueyuan. Analysis of clinical trials of dermatological drugs in China, 2020 [J]. Chinese Journal of Dermatology, 2021, 54(11): 1001-1004.
[9]	Luo Shuaihantian, Long Hai, Lu Qianjin. Advances in systemic lupus erythematosus in 2018 [J]. Chinese Journal of Dermatology, 2020, 53(8): 665-667.
[10]	Wang Gang, Gu Heng, Zheng Min, Zhao Yi, Gu Jun, Jin Hongzhong, Liu Xiaoming, Shi Yuling, Sun Qing. Guidance on the use of biologic agents in psoriatic patients during COVID-19 outbreak [J]. Chinese Journal of Dermatology, 2020, 53(5): 317-318.
[11]	Qi-Quan CHEN. [J]. Chinese Journal of Dermatology, 2015, 48(4): 274-274.
[12]	. Butyl flufenamate ointment in the treatment of solar dermatitis: a clinical observation [J]. Chinese Journal of Dermatology, 2014, 47(6): 431-432.
[13]	GUO Qing, ZENG Fan-qin, CHEN Jian-hao, CHEN Hui-xia, ZHU Shuang. The treatment efficacy of 308-nm excimer laser for vitiligo [J]. Chinese Journal of Dermatology, 2007, 40(4): 193-195.
[14]	HUANG Qiong, YANG Qin-ping, FANG Xu, HAN Ling, ZHENG Zhi-zhong, FU Wen-wen, SUN Jian-fang, JIANG Yi-qun, GU Jun, GAO Chun-fang, XU Ai-e, CHEN Jun-fan, SU Bing-hua, HE Qing-bo. Treatment of psoriasis vulgaris with a recombinant human tumor necrosis factor receptor:Fc fusion protein:a multicentre, randomized, double blind trial [J]. Chinese Journal of Dermatology, 2007, 40(11): 655-658.
[15]	GONG Juan-qin, LIN Lin, HAO Fei, CHEN Yan, ZENG Fan-qin, LI Bo-you, BI Zhi-gang, ZHANG Mei-hua, YI Dong, ZHAO Bian. Staphylococcus aureus Colonization in Eczema and Atopic Dermatitis and Therapeutic effect of Combined Topical Treatment [J]. Chinese Journal of Dermatology, 2004, 37(9): 515-518.

Targeted therapy for systemic lupus erythematosus

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［36］

Related Articles 15

Metrics

Comments

Recommended 10